abstract |
The present invention provides effective treatment and/or treatment of diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, liver cancer, head and neck cancer, and gallbladder cancer and metastases thereof Combination therapy for prophylaxis is provided. |